Pre-diabetes is a disturbing trend in the population, who are at risk of developing type-two diabetes. The aim of this study was to determine the effects use of Aloe vera in different doses on glucose and lipid profile in pre-diabetic subjects.
This study was a double blind randomized controlled trial (72 subjects) with pre-diabetes symptoms in 3 groups consumed capsules twice a day: Aloe vera 300 mg (AL300), 500 mg (AL500) and placebo (PL). Fasting blood glucose (FBS), HbA1C and lipid profile were evaluated in baseline, 4 or 8 weeks. On-way ANOVA, Friedman, Wilcoxon, Kruskal-Wallis , Mann-Whitney and Chi-square tests were used for within or between groups statistical analysis.
FBS level in group AL300, showed significantly decreased in fourth week after the intervention, compared to PL in the same time (p = 0.001). Also, HbA1C level in this group at the eighth week after the intervention (p = 0.042), had a significant decrease. The levels of Total cholesterol and LDL-C, only in the group AL500 (p < 0.001 and p = 0.01), was significantly reduced, along with HDL-C level improvement just after eight weeks (p = 0.004). Triglyceride level showed a significant decrease (p < 0.045) just after four weeks use of AL500.
The Use of Aloe vera extract in pre-diabetic patients, could revert impaired blood glucose within four weeks, but after eight weeks could alleviate their abnormal lipid profile.
The present clinical trial was designed to evaluate the safety and efficacy of a polyherbal formulation (PHF) consisted of Allium sativum, Aloe vera, Nigella sativa, Plantago psyllium, Silybum marianum and Trigonella foenum-graecum for controlling dyslipidemia and hyperglycemia in patients with advanced-stage of type-2 diabetes. An open-label phase I trial was carried out on 30 patients who had hyperlipidemia and hyperglycemia before the beginning of the trial in spite of receiving statins and oral hypoglycemic drugs. Patients were given one PHF sachet two times daily for 40 consecutive days. All subjects also continuously received their statins and oral hypoglycemic agents. Clinical assessments and laboratory findings were evaluated before starting treatment and at day 40. Treatment with PHF had no significant effects on serum biochemical parameters related to liver and kidney functions, on hematological parameters related to erythrocytes, leukocytes, and platelets, and on body weight and blood pressure. After consumption of PHF, 2 patients complained of mild nausea, and 2 patients reported diarrhea. PHF significantly decreased fasting blood glucose and HbA1c from 162±40mg/dL to 146±37mg/dL and from 8.4±1.5% to 7.7±1.1%, respectively. Also, it significantly decreased the level of LDL from 138±25mg/dL to 108±36mg/dL, and the level of triglycerides from 203±47mg/dL to 166±58mg/dL. In conclusion, the present results demonstrated that the PHF was safe and efficacious in lowering the levels of blood glucose and serum lipids in patients with advanced-stage of type-2 diabetes.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Aloe Vera is one of the endemic plants in southern Iran, which has been mentioned in the textbooks of Persian medicine since 2500 years ago. The aim of this study was to compare the effectiveness and cost of Aloe Vera gel with conventional treatments in patients with chronic ulcers.
This comparative study was conducted on 60 patients with chronic ulcers (more than 3 weeks) in Al-Zahra hospital (Isfahan, Iran) in 2015. The participants were divided into two groups of 30 patients per group. In one group, we used conventional treatment plus Aloe Vera gel and in the other group, only the conventional treatment was used. In the Aloe Vera group, we used Aloe Vera gel twice a day. The patients were followed-up a week after the treatment and then monthly for 3 months.
The male: female ratio was 1:1 in each group. The mean age of the Aloe Vera and control groups were 62.3±11.2 and 63.1±9.6, respectively. After three months follow-up, wound healing occurred in 28 (93.3%) patients in the Aloe Vera group and 14 (46.7%) patients in the control group (P<0.05). The overall mean time of wound healing was 31.25±11.2 and 63.2±20.4 in the Aloe Vera and control groups, respectively (P<0.05). The mean hospitalization time was 35.2±6.4 and 67.4±8.9 in the Aloe Vera and control groups, respectively (P<0.05). The average cost of Aloe Vera gel and conventional treatment per patient was $2 and $10 daily, respectively (P<0.05).
Aloe Vera gel is a beneficial treatment and cost effective for patients with chronic ulcers. The use of Aloe Vera gel in chronic ulcer is recommended in developing countries to lessen the financial burden.
Stomatitis is the most common complication of chemotherapy. This study aimed to assess the effect of aloe vera solution on stomatitis and its pain intensity in patients undergoing chemotherapeutic procedures.
In this randomized controlled clinical trial, 64 patients with Acute Myeloid Leukemia and Acute Lymphocytic Leukemia undergoing chemotherapy were randomly divided into a control and an intervention group. The intervention group patients were asked to wash their mouths with 5 ml of aloe vera solution for two minutes three times a day for 14 days. The control group patients, however, used only the ordinary mouthwashes recommended in hematologic centers. The patients' mouths were examined by two assistants on days 1, 3, 5, 7, and 14. The intensity of stomatitis was recorded according to WHO stomatitis intensity checklists and pain was evaluated using Visual Analog Scale. The data were analyzed by SPSS statistical software, version 18.
The results showed that aloe vera solution mouthwash significantly reduced the intensity of stomatitis and its pain in the intervention group compared to the control group. On the first day, no significant difference was found between the two groups regarding the mean intensity of stomatitis (P=0.178) and pain (P=0.154). However, a significant difference was observed between the two groups in this regard on other days (days 3-14: P=0.001 for stomatitis intensity, P=0.001 for pain).
Aloe vera solution can improve the patients' nutritional status, reduce stomatitis and its pain intensity, and increase the patients' satisfaction. Trial Registration Number IRCT2014092819318N1.
Aloe vera (Aloe vera (L.) Burm.f., Xanthorrhoeaceae family) has long been used in folk or traditional medicine for diabetes. Several studies have been conducted on the effect of Aloe vera on glycaemic control, but the results appear inconsistent. We undertook a systematic review and meta-analysis to assess the effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes.
A comprehensive literature search was conducted through MEDLINE, CENTRAL, CINAHL, Scopus, http://clinicaltrials.gov, Web of Science, Proquest, LILACS, HerbMed, NAPRALERT and CNKI to the end of January 2016 without language restriction. Historical search of relevant articles and personal contact with experts in the area were also undertaken. Studies were included if they were (1) randomized controlled trials of Aloe vera aimed at assessing glycaemic control in prediabetes or type 2 diabetes and (2) reporting fasting plasma glucose (FPG) or haemoglobin A1c (HbA1c ). Treatment effect was estimated with mean difference in the final value of FPG and HbA1c between the treatment and the control groups.
Eight trials involving 470 patients (235 each for prediabetes and type 2 diabetes) were included. In prediabetes, Aloe vera significantly improved FPG (mean difference -0·22 mmol/L, 95% CI -0·32 mmol/L to -0·12 mmol/L, P < 0·0001), with no effect on HbA1c (mean difference -2 mmol/mol, 95% CI -5 mmol/mol to 1 mmol/mol). Aloe vera may improve glycaemic control in type 2 diabetes, with a marginal improvement in FPG (mean differences -1·17 mmol/L, 95% CI -2·35 mmol/L to 0·00 mmol/L, P = 0·05) and a significant improvement in HbA1c (mean difference -11 mmol/mol, 95% CI -19 mmol/mol to -2 mmol/mol, P = 0·01).
The current evidence suggests some potential benefit of Aloe vera in improving glycaemic control in prediabetes and type 2 diabetes. However, given the limitations of the available evidence and the high heterogeneity in study results, high-quality, well-powered randomized controlled trials using standardized preparations are needed to quantify any beneficial effects of Aloe vera on glycaemic control.
The aim of this study was to investigate the effect of Aloe vera gel extract on plasma total antioxidant capacity (TAC) and oral pathogenic bacteria in healthy volunteer.
Fifty-three healthy volunteers were participated and interviewed for history of allergy, current systemic diseases and medications. Participants were received 250 mL of A. vera gel extract daily for 14 consecutive days. At days 0 and 15 of the experiment, blood samples were collected and analyzed for biochemical markers. The plasma TAC was evaluated by ferric reducing ability of plasma technique. The biochemical markers, including aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total protein (TP), serum albumin (ALB), serum globulin (GLB), total bilirubin (TB), blood urea nitrogen (BUN), serum creatinine (Cr) and creatinine clearance (CrCl) were measured. The antibacterial effect of A. vera gel extract against Lactobacillus spp. and Streptococcus mutans was also investigated. Statistical analysis was performed using paired t-test to compare between baseline and 14 days post-intervention.
Neither allergy nor side effects of A. vera gel extract was detected. After 14 days of A. vera gel extract consumption, plasma TAC was significantly greater than that of baseline (p = 0.001). ALP, TB, TP and GLB were significantly increased (p < 0.05) which were still within normal range. AST, ALT, ALB, BUN, Cr and CrCl were not significantly different. A. vera gel extract significantly reduced the number of Lactobacillus spp. (p < 0.05), not S. mutans.
Our data revealed that A. vera gel extract significantly increased plasma TAC, and decreased the number of Lactobacillus spp. without any clinical side effects.
Ninety non-insulin dependent diabetic subjects were selected from Punjab Agricultural University and Civil hospitals of Ludhiana. The selected subjects were divided into three groups viz. Group I, II and III having thirty subjects each. The subjects of group I were not given any treatment. The subjects of group II and III were supplemented with 100 mg and 200 mg of Aloe vera L. gel powder respectively for a period of 3 months and supplementation was continued along with nutrition counselling for the next 3 months. The nutrition education was given for 3 months after 15 days interval to the subjects of group II and III through individual and group contact. The blood glucose and lipid profile were analyzed. The blood pressure of the subjects was also measured. It was seen that there was a significant (p ≤ 0.01) reduction in fasting blood glucose level by 11.4% and 15.4% and post prandial glucose level 18.5% and 27.8% in the subjects of group II and III respectively after the study. Significant (p ≤ 0.01) reduction in total cholesterol 8.6% and 10.1%, triglycerides 9.6% and 12.2%, low density lipoprotein cholesterol (LDL-C) 12.8% and 14.6%, very low density lipoprotein cholesterol (VLDL-C) 9.6% and 12.2% and an increase in high density lipoprotein cholesterol (HDL-C) 7.3% and 9.4% was observed in the subjects of group II and III respectively. The ratio of total cholesterol to HDL-C reduced from 5.6 to 4.8 and 6.1 to 5.0 and LDL-C to HDL-C from 3.7 to 3.0 and 4.1 to 3.1 in the subjects of group II and III respectively after the study. There was also a significant decrease (p ≤ 0.01) in the blood pressure of the subjects of group II and III and a non significant decrease (p ≤ 0.01) was seen in the subjects of group I. With the intervention of Aloe vera L., significant reduction was observed in blood glucose, lipid profile and blood pressure of the diabetic patients.
The metabolic effects of an aloe vera gel complex (Aloe QDM complex) on people with prediabetes or early diabetes mellitus (DM) are unknown. The goal of this study was to determine the effects of Aloe QDM complex on body weight, body fat mass (BFM), fasting blood glucose (FBG), fasting serum insulin, and Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) in obese individuals with prediabetes or early DM who were not on diabetes medications.
Participants (n = 136) were randomly assigned to an intervention or a control group and evaluated at baseline and at 4 and 8 wk.
The study lost six participants in the control group and eight in the intervention group. At 8 wk, body weight (P = 0.02) and BFM (P = 0.03) were significantly lower in the intervention group. At 4 wk, serum insulin level (P = 0.04) and HOMA-IR (P = 0.047) were lower in the intervention group; they also were lower at 8 wk but with borderline significance (P = 0.09; P = 0.08, respectively). At 8 wk, FBG tended to decrease in the intervention group (P = 0.02), but the between-group difference was not significant (P = 0.16).
In obese individuals with prediabetes or early untreated DM, Aloe QDM complex reduced body weight, BFM, and insulin resistance.
Clinical Trials of Cassia Auriculata across the globe on diabetic control
Co-administration of CA with MT at varying dose showed a synergistic herb-drug interaction. Thus using the synergistic herb-drug interaction, the dose level of MT may be reduced to produce the same therapeutic effect as when taken alone.
Cassia auriculata flower extract (CFEt), at doses of 0.15, 0.30 and 0.45 g/kg body weight for 30 days, suppressed the elevated blood glucose and lipid levels in diabetic rats. Cassia auriculata at 0.45 g/kg was found to be comparable to glibenclamide.
A concomitant increase in the antiperoxidative enzymes namely catalase, glutathione peroxidase and superoxide dismutase in serum, liver and kidney of CFP treated diabetic rats was observed. Also, an increase in the non-enzymic antioxidants, vitamin E and reduced glutathione and decrease in ascorbic acid was observed. This indicates that these herbal powders play an important role in scavenging toxic intermediates of incomplete oxidation in the body. Antiperoxidative effect of 200 mg CFP was much more significant than that of 100 mg of CFP.
The researchers at Greenwich aim to isolate and identify certain extracts from the plants Cassia auriculata and Cassia alata, which could have ‘active ingredients’ for treating diabetes. They discovered that one of the compounds isolated from the plant, kaempferol 3-O-rutinoside, has proved to be over eight times more potent than the standard anti-diabetic drug, acarbose.
A safety study of TAHITIAN NONI Juice from Tahiti was conducted with ninety-six healthy volunteers. For 28 days, participants consumed one of four daily quantities of noni juice: 0 mL (placebo), 30 mL, 300 mL, or 750 mL. All daily dose formulations were standardized to 750 mL by making up any volume differences with the placebo. Hematology, biochemistry, urinalysis, vital signs, and adverse events measurements were made at 0 (baseline), 2, and 4 weeks, as well as during a two-week follow up (week 6). Electrocardiogram (ECG) measurements were also made for each volunteer during the pre-study screen and at week 6. During the trial, those in the noni groups experienced 20 to 50% fewer total adverse events than those in the placebo group. A marginally significant (P<0.1) reduction in the number of constant adverse events experienced by the volunteers was also found in the 300 mL noni juice group. A similar trend was observed in the other noni juice groups, as well. No other clinically significant differences between any of the groups were noted in the parameters and measurements of this study, nor was there evidence suggesting any adverse dose-related effects. The results of this study indicate that drinking up to 750 mL TAHITIAN NONI Juice per day is safe.
Cigarette smoke-induced oxidative stress leads to dyslipidemia and systemic inflammation. Morinda citrifolia (noni) fruit juice has been found previously to have a significant antioxidant activity. One hundred thirty-two adult heavy smokers completed a randomized, double blind, placebo-controlled clinical trial designed to investigate the effect of noni juice on serum cholesterol, triglyceride, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), high-sensitivity C-reactive protein (hs-CRP), and homocysteine. Volunteers drank noni juice or a fruit juice placebo daily for one month. Drinking 29.5 mL to 188 mL of noni juice per day significantly reduced cholesterol levels, triglycerides, and hs-CRP. Decreases in LDL and homocysteine, as well increases in HDL, were also observed among noni juice drinkers. The placebo, which was devoid of iridoid glycosides, did not significantly influence blood lipid profiles or hs-CRP. Noni juice was able to mitigate cigarette smoke-induced dyslipidemia, an activity associated with the presence of iridoids.
This review investigated the relationship of noni juice, or its extract (fruit, leaves or root), to anticancer and/or immunostimulant properties. A Medline search was conducted using the key search words 'Morinda citrifolia' and 'Morinda citrifolia and cancer' (1964 to October, 2011) along with cross-referencing. Botanical and chemical indexes were not included. A total of 304 and 29 (10%) articles, respectively, were found under these key terms. Of the 19 studies actually related to cancer, seven publications were in vitro cancer studies, nine were in vivo animal cancer studies, and three were in vivo human cancer studies. Among the in vitro studies, a 'concentrated component' in noni juice and not pure noni juice may (1) stimulate the immune system to 'possibly' assist the body fight the cancer, and (2) kill a small percentage (0-36%) of cancer cells depending on the type. The nine animal studies suggest that a concentrated component in noni juice may stimulate the immune system; but only slightly increases the number (about 1/3; 25-45%) of surviving mice. Other than two case studies, only two human clinical studies existed. The first consisted of testing freeze-dried noni fruit, which reduced pain perception, but did not reverse advanced cancer. The second was on smokers ingesting an unknown concentration of noni juice who experienced decreased aromatic DNA adducts, and decreased levels of plasma superoxide anion radicals and lipid hydroperoxide. Factors to consider in the future are clearly defining the substance being tested, and whether or not the juice is pasteurized. Some reports of hepatotoxicity exist, although there were confounding factors in most of the case reports. More importantly, noni juice is high in potassium and needs to be monitored by patients with kidney, liver or heart problems. In conclusion, a few in vitro and in vivo animal studies suggest a possible unidentified substance in unpasteurized noni fruit juice that may have a small degree of anticancer activity. The isolation of the active component warrants further research